Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma

Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies

Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma